Press Release

TORONTO, June 13, 2018 /CNW/ – OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Aleafia Health Inc. (TSX-V: ALEF; OTCQX: ALEAF), a Canadian vertically integrated medical cannabis company, has qualified to trade on the OTCQX® Best Market.

OTCQX provides Aleafia with exposure to both institutional and retail investors through major online and full-service brokerage firms. Trades are settled and cleared in the United States similar to any NASDAQ or NYSE stock, and trade reports are disseminated through major financial data providers.

The OTCQX Best Market is the highest tier of the OTC markets reserved for established, investor-focused U.S. and international companies. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, be current in their disclosure, and have a professional third-party sponsor introduction. The companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications.

Aleafia Health begins trading today on OTCQX under the symbol “ALEAF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

“We are pleased to welcome Aleafia Health to the OTCQX Best Market,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “Aleafia Health joins more than 25 Canadian companies that upgraded to the OTCQX market thus far this year. We look forward to supporting the company as it continues to build its visibility within the U.S. market.”

“American investors can now embark on Aleafia’s journey of rapid growth. Trading on the OTCQX Best Market is an important milestone for Aleafia which will provide greater exposure, accessibility and liquidity for our current and potential shareholder base,” stated Julian Fantino “From ‘seed to sale,’ Aleafia takes a patient-first, physician-led and research-driven approach to medical cannabis care,” said Fantino. Fantino previously served as former Government of Canada Cabinet Minister and is the current Executive Chairman of Aleafia Health.

“With more than 20 clinics nationwide, over 40,000 patients since inception, and with a fully funded 317,000 sq. ft of modern fully automated production space coming online, this translates to over 38,000 kg of annual growing capacity by the end of 2019. As a result, Aleafia is uniquely positioned for success,” said Raf Souccar, former Deputy Commissioner of the Royal Canadian Mounted Police and current President and CEO of Aleafia Health. Mr. Souccar also served on current Canadian Prime Minister Justin Trudeau’s marijuana legalization task force.

Aleafia Health was sponsored for OTCQX by J.P. Galda & Co., a qualified third-party firm responsible for providing guidance on OTCQX requirements and recommending membership.

For Investor Relations, please contact:

IR@AleafiaInc.com  

For Media Relations, please contact:

Nicholas Bergamini, VP Public Affairs

416-860-5665 ext. 224

Media@AleafiaInc.com

About Aleafia Health Inc.:

Aleafia is a leading, vertically integrated medical cannabis company with a unique focus on delivering quality patient care from “seed” to “sale.” Aleafia is uniquely positioned with a singular focus on the medical cannabis market. The company operates the largest brick and mortar medicinal cannabis clinic network in Canada under the Canabo Medical Clinic brand, which is staffed by licensed, practicing physicians. Aleafia has obtained over 50,000 unique patients and maintains the largest medical cannabis patient data set in Canada. Aleafia’s state of the art production facilities will allow for the production of high- quality strains at low cost. Aleafia’s production will focus on securing the highest- quality medicinal product for its growing patient base.

Neither Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations.  When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information.  The forward-looking statements and information in this press release includes information relating to the implementation of Aleafia Health’s business plan.  Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, among others, the following risks: risks associated with the implementation of Aleafia Health’s business plan and matters relating thereto, risks associated with the cannabis industry, competition, regulatory change, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company’s common share price and volume.  Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change.  Investors are cautioned against attributing undue certainty to forward-looking statements.